Cancer Diagnostics Market


Cancer Diagnostics


Share, Global Trends,

Analysis, Research, Report,


Segmentation and Forecast,


Future Market Insights

Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting

services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,

technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.

We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.

Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and


We have a global presence with delivery centers across India specializing in providing global research reports and country

research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.

We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for

our client.

Research Capabilities

• Customized Research

• Syndicated Research

• Investment Research

• Social Media Research

Sector Coverage

• Automotive and Transportation

• Electronics, Semiconductor, and ICT

• Retail and Consumer Products

• Industrial Automation and Equipment

• Chemicals & Materials

• Food and Beverages

• Services and Utilities

• Energy, Mining, Oil, and Gas







Social Media


Subscription Information

For detailed subscription information please contact

Hari. T (Sr. Manager - Global Business Development)

T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268


Report Description

Cancer is characterized by the growth of abnormal cells that divide uncontrollably and

have the ability to infiltrate and destroy normal body tissue. Cancer is triggered by both

external factors such as tobacco, chemicals, alcohol, infectious organisms, sun exposure

and internal factors such as hormones, inherited gene mutations, immune conditions and

abrupt mutations. Cancer can start almost anywhere in the human body and has the

ability to spread all over the body. Cancers are majorly solid tumors (tissue masses) and

blood cancers (leukemia). There are more than 100 types of cancers such as lung cancer,

colorectal, breast, blood cancers, etc. Cancer is the second-leading cause of death in the

United States. But survival rates have improved for many types of cancer due to

continuous development of screening and treatment procedures. The most common

cancer diagnostic methods are biopsy, sentinel node biopsy, endoscopy, blood tests, bone

marrow aspiration, Pap test, sputum and bronchial washing analysis, imaging studies,

genetic analysis, etc. The diagnosis of cancer involves collection of patient samples such

as a cell or tissue or cells’ proteins, DNA, and RNA followed by detection of specific


Browse Full Report@

Cancer Diagnostics Market: Drivers and Restraints

Cancer diagnostics market is witnessing high growth due to increasing prevalence and

incidences of several types of cancers. Major drivers for the global cancer diagnostic

market are technologically advanced and increasing point-of-care diagnostics, cost-

Report Description

Additionally, increasing persistence to provide best-in-class healthcare services with high

accuracy and efficiency towards patient is expected to fuel the global cancer diagnostics

market across the globe. However, lack of adequate reimbursement policies for novel

technologies and stringent regulatory procedures particularly for United States are the

major factors that can hamper the global cancer diagnostics growth over the forecast


Cancer Diagnostics Market: Segmentation

The global cancer diagnostics market has been classified on the basis of product,

application, end use and geography.

Based on product type, the global cancer diagnostics market is segmented into the




Tumor Biomarkers

Based on application type, the global cancer diagnostics market is segmented into the


Liver Cancer

Blood Cancer

Report Description

Colorectal Cancer

Kidney Cancer

Breast Cancer

Ovarian Cancer

Lung Cancer

Prostate Cancer

Pancreatic Cancer

Other Cancers

Request For TOC@

Based on end use type, the global cancer diagnostics market is segmented into the



Diagnostic centers


Home care

Report Description

Cancer Diagnostics Market: Overview

North America was the key region in global cancer diagnostics market in terms of

revenue in 2014, followed by Europe. The first FDA-cleared assay for breast cancer

diagnosis was In Vitro Diagnostic Multivariate Index Assays (IVDMIA). The "MammaPrint"

and “BluePrint” assays for breast cancer diagnosis and a microarray-based gene

expression assay "ColoPrint" for predicting the recurrence of stage II and III colon cancer,

has recognized the potential of cancer/tumor profiling in diagnostics and prognosis. This

scenario is anticipated to revolutionize the cancer diagnostics companies and boost

growth in global cancer diagnostics market in the coming five to 10 years. By product

type, genomic biomarkers are dominating as compared to other product types in global

cancer diagnostics market. For instance, GUARDANT360 blood test, next generation

sequencing test 'Cologuard', Cobas HPV Test, and myRisk Hereditary Cancer multigene

molecular diagnostic test are few examples of genomic biomarkers. By end use, hospitals

and diagnostic centres segments held 50% share in the global cancer diagnostic market

and the trend is forecast to continue through 2025. The altering regulatory consequences

among the high growth countries of Asia Pacific is attracting the leading companies in the

global cancer diagnostics market.

Request Free Report Sample@

Cancer Diagnostics Market: Key Players

Report Description

Key players of cancer diagnostics market are M Genomics Ltd., Abbott Laboratories,

Agena Bioscience Inc., Alere Inc., Astra Biotech GmbH, bioMérieux SA, BioMosaics,

Biotype Diagnostic GmbH, Cancer Genetics, Inc., CDx Diagnostics, Celerus Diagnostics,

Inc., Cube Dx GmbH, Dako A/S (an gilent company), EntroGen, Inc., Epigenomics AG,

Exact Sciences Corporation, GE Healthcare, Genalyte, Inc., GeneCentric Diagnostics, Inc.,

GeneDx,., Genomic Vision, Genoptix (a Novartis company), Hologic, Inc., Illumina, Inc.,

Inform Genomics, Inc., Mayo Medical Laboratories and Mayo Clinic, MBL International

Corporation, NanoIVD, Inc., NanoString Technologies, Inc., NewGene Ltd., OncoPlex

Diagnostics (OncoPlexDx), Oncospire Genomics, Oxford Cancer Biomarkers Ltd., Oxford

Gene Technology, PrognosDx Health, Inc., Provista Diagnostics, Inc., QuantuMDx Group,

Quest Diagnostics, Rheonix, Inc., Rosetta Genomics Ltd., Siemens Healthcare Diagnostics,

Thermo Fisher Scientific, Inc., Transgenomic, Inc., TrimGen Corporation, TrovaGene, Inc.,

Ventana Medical Systems, Inc. Getting regulatory approvals for in vitro cancer diagnostics

in Europe is easy as compared to United States. So preferably most of the cancer

diagnostic companies are launching their new innovative products in Europe and

consequently applying for FDA in the United States.

Thank You!

To know more about us, please visit our website:

For sales queries or new topics email us on:

For other queries contact: Mr. Sudip Saha

Future Market Insights: 616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989, United States

T: +1-347-918-3531 | D: +1-845-579-5705

More magazines by this user
Similar magazines